Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.

To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com . A replay of the webcast will be available for up to a year.

About Bio-Rad

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, BIO-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety, and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com .

Investor Contact:
Ruben Argueta, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

News Provided by Business Wire via QuoteMedia

BIO
The Conversation (0)
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

(TheNewswire) Third pharmaceutical company relationship entered Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an... Keep Reading...
Lexaria Celebrates its 70th Patent Award

Lexaria Celebrates its 70th Patent Award

KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is... Keep Reading...
Lexaria Announces Results From Animal Study GLP-1-A26-1

Lexaria Announces Results From Animal Study GLP-1-A26-1

(TheNewswire) Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC October 15, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following... Keep Reading...
Lexaria Announces Results from Animal Study GLP-1-A26-1

Lexaria Announces Results from Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation... Keep Reading...

Interactive Chart

Latest Press Releases

Related News